Oyster Therapeutics Raises $60M From London-based 4bio Capital

Oyster Therapeutics, a London, UK-based pharmaceutical company formerly recognized as Kesmalea Therapeutics, has successfully secured $60M in a Series A+ funding round, led by 4BIO Capital based in London.

Details regarding other investors and specific use of the funds were not disclosed.

The company focuses on developing pharmaceutical solutions and serves a diverse clientele within the healthcare sector. Their approach is centered around delivering therapeutics that aim to address significant unmet medical needs, showcasing their commitment to advancing patient care.

Oyster Therapeutics has made substantial progress in its field, reinforcing its position within the pharmaceutical landscape. The company's dedication to research and development is indicative of its potential for future achievements.

The CEO, Jeffrey Nau, leads the team at Oyster Therapeutics, guiding its strategic direction and ensuring alignment with its mission to enhance healthcare outcomes.

The company was originally founded under the name Kesmalea Therapeutics, signifying its evolving journey in the pharmaceutical domain.

Company	Oyster Therapeutics
Round	Series A+
Amount	$60M
Lead Investor	London-based 4BIO Capital
Founders	Jeffrey Nau
Sectors	Pharmaceuticals